Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Nov 30, 2020

Company Overview

Cryo-Cell International Inc., founded in 1989, is the world’s first private cord blood bank and is internationally recognized as the industry leader.  More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. Cryo-Cell’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, and support the advancement of regenerative medicine. Cryo-Cell aims to help more patients significantly improve their lives through the utilization of the unique immunomodulatory and potential regenerative properties found in the cord blood and cord tissue. In February 2021, Cryo-Cell entered into an exclusive, collaborative license agreement with Duke University that grants Cryo-Cell the rights to certain intellectual property, proprietary processes and regulatory/clinical data related to cord blood and cord tissue developed at The Marcus Center for Cellular Cures at Duke University. Cryo-Cell anticipates opening infusion clinics to treat patients with conditions such as autism, cerebral palsy, and traumatic brain injuries under the rights granted to Duke University through the FDA’s Expanded Access Program.  In addition to these, the license agreement includes other clinical indications currently being studied, such as adult stroke, multiple sclerosis, osteoarthritis and COVID-19.

Investor Contact Information

Corporate Headquarters

Cryo-Cell International, Inc.
700 Brooker Creek Boulevard
Suite 1800
Oldsmar, FL 34677
T: 800-786-7235

Investor Relations

Irene Smith
Executive Assistant / Office Manager
T: 813-749-2102
Investors@cryo-cell.com

Transfer Agent

Continental Stock Transfer and Trust Company
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com